News & Updates
Filter by Specialty:
RSV may worsen clinical outcomes in HF patients
A retrospective analysis presented at HSFA ASM 2024 shows that respiratory syncytial virus (RSV) infection in individuals with heart failure (HF) is associated with greater adverse clinical outcomes.
RSV may worsen clinical outcomes in HF patients
01 Nov 2024
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients
21 Oct 2024
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
A treatment regimen combining tislelizumab, anlotinib, and two cycles of irinotecan in the second-line setting demonstrates favourable efficacy and safety in patients with extensive-stage small cell lung cancer (ES-SCLC), according to the results of the single-arm phase II ESTAIL study.
Second-line tislelizumab + anlotinib + chemo shows potential to improve ES-SCLC survival
19 Oct 2024
AI tool reads histology slides to predict lung cancer mutations
DeepGEM, a novel tool that harnesses artificial intelligence (AI), delivers accurate, timely, and economical gene mutation prediction from routinely acquired histology slides, enhancing the efficiency of lung cancer mutation screening, according to a study.
